Veradermics Announces Pricing of Upsized Public Offering and Private Placement
Veradermics, Incorporated (NYSE: MANE) announced the pricing of an upsized public offering of 3,843,790 shares of its common stock at $100.00 per share, expecting to generate approximately $384.4 million in gross proceeds. Concurrently, the company is conducting a private placement of 300,000 pre-funded warrants to affiliates of Suvretta Capital, anticipating around $30.0 million in gross proceeds. Both offerings are expected to close on May 1, 2026, and the funds will support the clinical-stage biopharmaceutical company focused on developing therapeutics for pattern hair loss.
APR 28·Clinical Trials Arena▲
Veradermics’ stock grows on pivotal hair loss win
Veradermics' stock surged over 47% after its oral minoxidil drug, VDPHL01, showed significant improvements in a pivotal Phase II/III trial for male pattern baldness. The treatment demonstrated superior hair growth and patient-reported benefits compared to placebo and was well-tolerated. If approved, VDPHL01 could be the first non-hormonal pill for pattern hair loss to receive FDA clearance in nearly three decades, potentially tapping into a $2 billion or more market opportunity.
MAR 31·Stock Titan▲
Veradermics (NYSE: MANE) bets on oral minoxidil for pattern hair loss
Veradermics (NYSE: MANE) is a late clinical-stage biopharmaceutical company focusing on developing VDPHL01, an extended-release oral minoxidil for treating pattern hair loss (PHL) in both men and women. The company is conducting three registration-directed, placebo-controlled trials for VDPHL01. Veradermics estimates the U.S. PHL treatment market at approximately $9 billion annually and plans a cash-pay, multi-channel commercial strategy, leveraging its patent protection expected to extend into at least 2043.
